- CUSIP
- 032108532
- Issuer
- Amplify
- Inception Date
- May 20, 2024
- Category
- Health & Biotech Equities
- Leveraged
- 1x (No leverage)
- Index Tracked
- VettaFi Weight Loss Drug & Treatment Index
- Distribution Policy
- Distributing
- Asset Class
- Equity
- Asset Class Size
- Large-Cap
- Asset Class Style
- Blend
- Assets Under Management
- $4M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
THNR Performance Chart
Amplify Weight Loss Drug & Treatment ETF (THNR) is up 1.7% since the beginning of the year. THNR is currently trading at $26 per share.
Loading charts...
Returns By Period
Amplify Weight Loss Drug & Treatment ETF (THNR) has returned 1.67% so far this year and 13.44% over the past 12 months.
Amplify Weight Loss Drug & Treatment ETF
- 1D
- -1.11%
- 1M
- 4.99%
- 6M
- -2.05%
- YTD
- 1.67%
- 1Y
- 13.44%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.79%
- 1M
- 1.13%
- 6M
- 7.71%
- YTD
- 9.79%
- 1Y
- 20.06%
- 3Y*
- 18.60%
- 5Y*
- 11.43%
- 10Y*
- 13.27%
THNR Monthly Returns History
Based on dividend-adjusted daily data since May 21, 2024, THNR's average daily return is +0.01%, while the average monthly return is +0.21%. At this rate, an investment would double in approximately 27.5 years.
Historically, 52% of months were positive and 48% were negative. The best month was Nov 2025 with a return of +11.6%, while the worst month was Mar 2025 at -8.3%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 4 months.
On a daily basis, THNR closed higher 51% of trading days. The best single day was Apr 9, 2025 with a return of +5.2%, while the worst single day was Apr 4, 2025 at -6.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.90% | -0.93% | -5.29% | -0.36% | 1.75% | 3.08% | -0.19% | 1.67% | |||||
| 2025 | 2.57% | 1.51% | -8.27% | 2.26% | 1.03% | 2.02% | -1.11% | 2.12% | 2.10% | -0.46% | 11.62% | -1.46% | 13.65% |
| 2024 | -0.38% | 2.90% | 1.03% | 7.05% | -4.94% | -5.64% | -5.03% | -5.22% | -10.47% |
Benchmark Metrics
Amplify Weight Loss Drug & Treatment ETF has an annualized alpha of -7.70%, beta of 0.65, and R2 of 0.29 versus S&P 500 Index. Calculated based on daily prices since May 21, 2024.
- This ETF participated in 108.15% of S&P 500 Index downside but only 40.75% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.65 may look defensive, but with R2 of 0.29 this ETF is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this ETF's risk.
- R2 of 0.29 means this ETF moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -7.70%
- Beta
- 0.65
- R²
- 0.29
- Upside Capture
- 40.75%
- Downside Capture
- 108.15%
Expense Ratio
THNR has an expense ratio of 0.59%, placing it in the medium range.
Return for Risk
Risk / Return Rank
THNR ranks 25 for risk / return — below 25% of ETFs on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Amplify Weight Loss Drug & Treatment ETF (THNR) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| THNR | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.91 | ||
| Sortino ratioReturn per unit of downside risk | -1.08 | ||
| Omega ratioGain probability vs. loss probability | 1.13 | 1.29 | -0.16 |
| Calmar ratioReturn relative to maximum drawdown | 1.12 | 2.21 | -1.10 |
| Martin ratioReturn relative to average drawdown | 2.43 | 9.61 | -7.18 |
Dividends
Dividend History
Amplify Weight Loss Drug & Treatment ETF provided a 1.61% dividend yield over the last twelve months, with an annual payout of $0.41 per share.
| Period | TTM | 2025 | 2024 |
|---|---|---|---|
| Dividend | $0.41 | $0.41 | $0.22 |
Dividend yield | 1.61% | 1.64% | 0.98% |
Monthly Dividends
The table displays the monthly dividend distributions for Amplify Weight Loss Drug & Treatment ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.41 | $0.41 |
| 2024 | $0.22 | $0.22 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Amplify Weight Loss Drug & Treatment ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Amplify Weight Loss Drug & Treatment ETF was 32.51%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Amplify Weight Loss Drug & Treatment ETF drawdown is 6.69%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -32.51%Apr 2025 | 7mo 7d | — | 1y 10moSep 2024 - now |
2024 pullback2024 | -6.89%Aug 2024 | 23d | 8d | 1mo 1dJul 2024 - Aug 2024 |
2024 pullback2024 | -1.93%May 2024 | 8d | 5d | 13dMay 2024 - Jun 2024 |
2024 pullback2024 | -1.57%Jul 2024 | 7d | 7d | 14dJun 2024 - Jul 2024 |
2024 pullback2024 | -1.10%Jun 2024 | 7d | 6d | 13dJun 2024 - Jun 2024 |
Drawdown Indicators
| THNR | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -32.51% | -56.78% | +24.27% |
Max Drawdown (1Y)Largest decline over 1 year | -12.06% | -9.10% | -2.96% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -6.69% | -1.24% | -5.45% |
Average DrawdownAverage peak-to-trough decline | -12.06% | -10.71% | -1.35% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.54% | 2.09% | +3.45% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Build a portfolio with THNR
Add Amplify Weight Loss Drug & Treatment ETF to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with THNR